Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Retirement Ready: 3 Dividend Stocks to Set and Forget

These are three rock-solid dividend stocks you can buy now and confidently forget, knowing they’ll keep working for you year after year.

Don’t Miss These 4 Stocks With Explosive Dividend Yields

Don’t Miss These 4 Stocks With Explosive Dividend Yields

See which large-cap U.S. stocks offer the highest yields in healthcare, materials, utilities, and real estate. Their yields range from 6% to over 14%.

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

The Delaware Supreme Court has overturned a lower court’s decision that allowed expert testimony supporting plaintiffs’ claims in a high-profile case alleging that Zantac, or its generic ranitidine, can cause cancer.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence (BCR) at high…

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Wednesday’s Unusual Options Activity Reveals 3 Standout Long Straddle Plays

There were 37 unusually active options in Wednesday Trading that expire in 30 days. This DTE reveals three standout long straddle plays that provide a nice combination of time and cost, while allowing increased volatility to take its course.

Ursula von der Leyen faces confidence vote in far-right challenge

A range of accusations have been levelled against the European Commission president

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Von der Leyen survives censure vote but faces calls to reverse EU’s rightward drift

Von der Leyen survives censure vote but faces calls to reverse EU’s rightward drift

Debate on motion against European Commission president lifts lid on simmering discontent among MEPs

The Guardian - UK

Pfizer Earnings Preview: What to Expect

Pfizer Earnings Preview: What to Expect

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company’s bottom-line figure.

Top 5 Undervalued Dividend Stocks With Strong Payout Potential

Top 5 Undervalued Dividend Stocks With Strong Payout Potential

Seemingly undervalued dividend stocks, such as BAC, F, MO, VZ, and PFE, offer a rare combination of strong yields and attractive valuations.

Regulator warns of small risk of serious condition in people having RSV jab

Regulator warns of small risk of serious condition in people having RSV jab

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

Evening Standard

Turbulent research landscape imperils US brain gain − and ultimately American prosperity

Turbulent research landscape imperils US brain gain − and ultimately American prosperity

Despite representing only 4% of the world’s population, the United States accounts for over half of science Nobel Prizes awarded since 2000, hosts seven of The Times Higher Education Top 10 science universities, and incubates firms such as Alphabet (Google), Meta and Pfizer that turn federally funded discoveries into billion-dollar…

The Conversation

Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook

Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook

Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10-year historical average P/E ratio.

COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know

COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know

FDA has updated safety warnings for the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

MEPs seek Commission President von der Leyen's resignation with censure motion

Supporters of a motion of censure against Commission President Ursula von der Leyen hope it will put enough political pressure on her leadership to force a resignation – mirroring the 1999 downfall of Commission President Jacques Santer.

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

This blend of stocks may be the key to long-term success.

Unusually Active Put Options Signal Long Straddle Opportunity After Zoetis Downgrade

Stifel Financial downgraded Zoetis stock on Wednesday, causing the animal health company’s shares to fall 4% on the news. The analyst downgrade created a possible long straddle for options investors. The question is whether it’s the best strategy.

Is Pfizer Stock Underperforming the S&P 500?

Pfizer has underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Can Birth Control Give You Brain Tumors? These 400 Women Say The Pfizer Shot Did

Hundreds of women allege Pfizer's contraceptive injection caused tumors, accusing the company of ignoring known dangers and insufficient safety warnings.

Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

The Guardian - US

A ‘war on children’: as US changes Covid vaccine rules, parents of trial volunteers push back

Frustration and anger mount as Trump administration contemplates new trials and restrictions for Covid vaccines

"Brussels, my love?" Surrender summit or Reset Summit?

An EU–UK summit took place in London this week marking a significant step in post-Brexit relations.

Pfizer's 7.5% Dividend: Income Haven or House of Cards?

Pfizer's high dividend yield warrants scrutiny regarding its sustainability, given changing revenues and pipeline investments.

The Independent UK

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter

Commission's Pfizergate loss hailed as ‘victory for transparency’

The EU Court ruled against the Commission for failing to justify its refusal to release texts between von der Leyen and Pfizer’s CEO. Critics say the Commission’s actions undermine public trust and accountability, calling for greater transparency in decision-making.

1 … 8 9 10 11

People

177,870 stories

Robert F. Kennedy Jr

Ursula von der Leyen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Supreme Court

The New York Times

The European Union

European Commission

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prostate Cancer

Places

357,546 stories

135,395 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play